00

Investor Relations

Investor Relations

Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's products are based on the Staccato® system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.

ADASUVE® is Alexza's first commercial product and it has been approved for sale by the U.S. Food and Drug Administration and the European Commission. Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for ADASUVE in the U.S. Ferrer is Alexza's commercial partner for ADASUVE in Europe, Latin America and the Commonwealth of Independent States countries.

Stock Quote

ALXA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.49
Change (%) Stock is Down 0.02 (0.57%)
Volume89,051
Data as of 08/27/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

What's New

Download Documentation 2014 Annual Report

Recent News

More >>
DateTitle 
08/14/14Alexza Pharmaceuticals Provides an Update on the Five Post-EMA Approval Studies for ADASUVE®Printer Friendly Version
08/08/14Alexza Pharmaceuticals Announces the Launch of ADASUVE® (inhalation powder, loxapine) in GuatemalaPrinter Friendly Version
08/07/14Alexza Reports 2014 Second Quarter Financial ResultsPrinter Friendly Version
07/31/14Alexza Provides Pipeline UpdatePrinter Friendly Version

Upcoming Events

More >>
DateTitle
09/09/14 9:10 a.m. ET
Alexza Pharmaceuticals, Inc. at Morgan Stanley Healthcare Conference
LocationNew York, NY US

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.